Latest Articles and Analysis

The instruments to close the HIV and hepatitis C epidemics already exist: SHIELD, MMP, and the HCV clearance cascade have each lit up exactly the stage they were built to see. The gaps that remain aren't failures of science; they're failures of funding, and the December 2026 budget deadline will force a choice about whether we keep the capacity to measure at all.

Formulary cuts, fibrosis staging requirements making a comeback, and the near-disappearance of HCV charitable assistance programs — CANN's Q3 2026 HIV/HCV Co-Infection Watch maps a deteriorating access landscape for people living with HIV/HCV co-infection.

Q1 2026 Watch: HCV/HIV co-infection treatment access under evolving federal and state policies.

Q4 2025 Watch monitoring HCV treatment access and federal initiatives including Cure Hepatitis C Act.

Q3 2025 Watch: critical analysis including Cure Hepatitis C Act proposing subscription treatment models.

Q2 2025 Watch monitoring HCV and HIV treatment access through ADAPs, Medicaid, and federal assistance.

Q1 2025 Watch: comprehensive update on HIV/HCV co-infection treatment access across federal and state programs.

Q4 2024 Watch: HCV treatment access assessment with guidance for disaster-displaced individuals.

Elevated HCV prevalence among HIV-positive MSM and co-infection management implications.

Q3 2024 Watch monitoring HCV treatment access across ADAPs, Medicaid, Veterans programs, and assistance initiatives.

HCV co-infection in HIV-positive MSM: treatment barriers through ADAPs and policy recommendations.

Q2 2024 Watch: Prior authorization rollbacks in Medicaid HCV programs; ADAP and assistance program coverage.

Q1 2024 Watch: Pandemic Medicaid protections ended; millions lost coverage; ADAP and veterans updates.

Q4 2023 Watch: Bipartisan PEPFAR reauthorization push; ADAP coverage and Medicaid updates tracked.

HCV vaccine development requires addressing immune variability, access barriers, and community trust.

Q3 2023 Watch: HIV disparities coverage; debt ceiling crisis impacts; Medicaid disenrollment trends tracked.

Q2 2023 Watch: Braidwood decision impacts PrEP coverage; ADAP coverage analysis and Medicaid program updates.

Q1 2023 Watch: Tennessee rejecting federal HIV funding; updates on ADAPs, Medicaid, veterans care, and harm reduction.

Q4 2022 Watch: HHS renewed opioid emergency; CANN launched monkeypox project; HEPLISAV-B hepatitis B vaccine covered.

Monitoring report documents HCV treatment access challenges across ADAP, Medicaid, and VA systems.